Billionaire wild bets on Consumer Biotech, GLP-1s, and psychedelics | Christian Angermayer | E61

Christian Angermayer became a multimillionaire before turning 25 thanks to the merger of Alnylam with Ribopharma. We talk about his diverse investment appetite and the rise of consumer biotech and human enhancement.We talk about GLP-1s, the progress of AtaiBeckley, and why he thinks ‘going home and sleeping’ beats an all-nighter every time.

---Discover the best biotech companies in 🇪🇺 with the FlotBio Map at https://bit.ly/4nXmKjN---

⭐️ ABOUT THE SPEAKER

Christian is the founder of Apeiron Investment Group, which manages around $7 billion across psychedelics, longevity, consumer biotech, crypto and media. He also co-founded big companies including AtaiBeckley and the Enhanced Games.Christian studied business in Germany at the University of Bayreuth but dropped out to co-found Ribopharma, which merged with Alnylam Pharmaceuticals in 2003.

🔗 LINKS MENTIONED

• Christian Angermayer LinkedIn profile — https://www.linkedin.com/in/christian-angermayer/
• Enhanced Games — https://www.enhanced.com/
• Enhanced Games inaugural event press release — https://investors.enhanced.com/inaugural-enhanced-games-deliver-a-world-record-and-21-personal-bests-showcasing-that-living-enhanced-works/
• David Nutt LinkedIn profile — https://www.linkedin.com/in/professor-david-nutt-82498025/
• AtaiBeckley pipeline — https://www.ataibeckley.com/our-work/pipeline
• BBC weight loss drugs comparison — https://www.bbc.com/news/articles/c981044pgvyo
• David Nutt drug-harm chart — https://commons.wikimedia.org/wiki/File:HarmCausedByDrugsTable.svg
• Matthew Walker, *Why We Sleep* — https://www.amazon.com/Why-We-Sleep-Unlocking-Dreams/dp/1501144316
• Mayo Clinic report on resveratrol/red wine — https://www.mayoclinic.org/diseases-conditions/heart-disease/in-depth/red-wine/art-20048281
• CNBC — atai's 2021 Wall Street debut — https://www.cnbc.com/2021/06/18/peter-thiel-backed-psychedelic-start-ups-shares-pop-in-wall-street-debut.html
• Fortune article on Angermayer's uranium bet — https://fortune.com/crypto/2025/05/27/christian-angermayer-uranium-digital-german-billionaire-tether/
• Robert Nelsen, ARCH Venture Partners — https://www.archventure.com/team/robert-nelsen/

📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/christian-angermayer-glp-1s/

💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

• Newsletter: http://eepurl.com/h_fnmH
• LinkedIn: https://www.linkedin.com/company/flot-bio/
• X (Twitter): https://x.com/FlotBio

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.

⏰ TIMESTAMPS

• [00:00:00] Intro
• [00:02:38] Crazy Consumer Demand for Mounjaro, Zepbound and Ozempic
• [00:07:45] Clinical Trials and Side-Effects: Can GLP-1s Benefit Non-Obese People?
• [00:12:52] Prescriptions and Drug Risks
• [00:25:57] The Trade-offs of Weight Loss, Testosterone
• [00:33:18] Personal Optimization with Sleep and Diet
• [00:40:44] Consumer Biotech: Vanity, Muscle and Sex
• [00:47:12] AtaiBeckley and the Psychedelics Market
• [00:56:25] Christian Angermayer: Uni Dropout to Multimillionaire
• [01:03:53] Quick-Fire Questions